Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) COO Jim Wassil sold 3,000 shares of Vaxcyte stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $73.88, for a total transaction of $221,640.00. Following the completion of the sale, the chief operating officer now directly owns 175,935 shares in the company, valued at approximately $12,998,077.80. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Jim Wassil also recently made the following trade(s):
- On Tuesday, January 2nd, Jim Wassil sold 3,000 shares of Vaxcyte stock. The stock was sold at an average price of $63.91, for a total transaction of $191,730.00.
Vaxcyte Stock Performance
NASDAQ PCVX opened at $74.83 on Wednesday. The company has a market capitalization of $7.12 billion, a P/E ratio of -22.40 and a beta of 0.93. The company has a fifty day moving average of $61.84 and a 200-day moving average of $53.69. Vaxcyte, Inc. has a 52-week low of $34.11 and a 52-week high of $76.72.
Analyst Ratings Changes
A number of research analysts recently weighed in on PCVX shares. Needham & Company LLC reiterated a “buy” rating and issued a $58.00 price objective on shares of Vaxcyte in a research note on Tuesday, November 7th. Mizuho began coverage on shares of Vaxcyte in a research report on Thursday, December 7th. They set a “buy” rating and a $69.00 price target for the company. Bank of America boosted their price target on shares of Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Vaxcyte has a consensus rating of “Buy” and an average target price of $68.40.
Institutional Trading of Vaxcyte
Several hedge funds have recently added to or reduced their stakes in the business. Xponance Inc. lifted its stake in Vaxcyte by 3.0% in the fourth quarter. Xponance Inc. now owns 5,672 shares of the company’s stock worth $356,000 after purchasing an additional 163 shares during the last quarter. Ellsworth Advisors LLC raised its stake in shares of Vaxcyte by 2.6% during the fourth quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock valued at $506,000 after acquiring an additional 207 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Vaxcyte by 0.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock valued at $3,211,000 after acquiring an additional 296 shares during the last quarter. Strs Ohio raised its stake in shares of Vaxcyte by 3.9% during the fourth quarter. Strs Ohio now owns 10,700 shares of the company’s stock valued at $671,000 after acquiring an additional 400 shares during the last quarter. Finally, Alps Advisors Inc. raised its stake in shares of Vaxcyte by 0.6% during the third quarter. Alps Advisors Inc. now owns 69,305 shares of the company’s stock valued at $3,533,000 after acquiring an additional 426 shares during the last quarter.
Vaxcyte Company Profile
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
- Five stocks we like better than Vaxcyte
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Is the dip in Atlassian stock a sneaky buy opportunity?
- How to buy stock: A step-by-step guide for beginners
- Caterpillar stock hits new highs; time to ring the register?
- Most Volatile Stocks, What Investors Need to Know
- 5 medical stocks growing earnings by triple digits
Receive News & Ratings for Vaxcyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxcyte and related companies with MarketBeat.com's FREE daily email newsletter.